IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#	2

APPLICANT: ITOH, Yasuaki et al. SERIAL NO. Based on PCT/JP0003221 FILED: Herewith FOR: "NOVEL POLYPEPTIDE" **CERTIFICATE OF EXPRESS MAIL** I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express mail in an envelope addressed to the: Commissioner of Patents and Trademarks, 2900 Crystal Drive, Arlington, VA 22202. Express Mail No EL 895421612 US. Date: November 20, 2001 **Box Sequence Assistant Commissioner for Patents** Washington, D.C. 20231 SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NOVEL POLOYPEPTIDE SEQUENCE (check and complete this item, if applicable) 1. [] This replies to the Office Letter DATED_ NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added. A copy of the Office Letter is enclosed. IDENTIFICATION OF PERSON MAKING STATEMENT

(type or print name of person signing below)

2. I, CARA Z. LOWEN

3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the Novel Polypeptide sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. [] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other application)

(this application)

SEQ ID NO:

SEQ ID NO: 1-10

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. § 1.821(e).

E. [X] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

[] Because the tement is not made by a person ristered to practice before the Office, the Statement is verified as Equired in 37 C.F.R. § 1.821(b). F. [X] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter. [] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g). STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME

AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

[] a small entity. A statement:				
[] is attached.				
[] was already filed.				
[X] other than a small entity.				

EXTENSION OF TERM

6. NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a

7.	The proceedings herein are for a patent application and the provisions of 37 C.F § 1.136 apply.				
	(a) []			of time under 37 C.F.R. § 1.136 (fees: 37	
		C.F.R. § 1.1	/(a)(1)-(4)) for the tota	l number of months checked below:	
		Extension	Fee for other than	Fee for	
		(months)	small entity	small entity	
	[]	one month	\$110.00	\$ 55.00	
	[]	two months	\$380.00	\$ 190.00	
	[]	three months	\$870.00	\$ 435.00	
	[]	four months	\$1,360.00	\$ 680.00	
			Fee \$		
If a	an add	itional extensior	of time is required, p	lease consider this a petition therefor.	
		(c	heck and complete the ne	ext item, if applicable)	
		fee paid	on for more therefor of \$ months of extension	nths has already been secured, and the is deducted from the total fee due for now requested.	
Ex	tensior	n fee due with th	is request \$		
			OR		
	(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.				
			FEE PAYN	MENT	
8. [] Attached is a check in the sum of \$					
			o the stransmittal is attached	um of \$ d.	
			FEE DEFIC	IENCY	
9.					

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the

additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before

(Submission-"NOVEL POLYPEPTIDE" Sequence—page 4 of 5)

the deficiency is noted and content to charge is included, processing lays are encountered in returning the papers to the D finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33. If any additional extension and/or fee is required, charge Account No. _ SIGNATURE(s) DATE: NOV " 20, 2001 Attorney for Applicants DIKE, BRONSTEIN, ROBERTS & **CUSHMAN Intellectual Property Practice** Group of EDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209 [] Inventor [] Assignee of complete interest [] Person authorized to sign on behalf of assignee Tel. No.: (617) 439-4444 [X] Practitioner of record Reg. No. 38,227 [] Filed under Rule 34(a) [] RegistrationNo. Other []

cted, the application is held abandoned. In those

ances where authorization to

BOS2_182989.1

the deficiency is noted and